HDAC11

HDAC11 is the sole member of class IV histone deacetylases and represents the smallest zinc-dependent HDAC isoform, with distinctive catalytic properties that differentiate it from other HDAC family members^[1]^[2]. Mechanistically, HDAC11 functions as an epigenetic regulator that controls gene expression through deacylation and deacetylation reactions, and accumulating evidence indicates that its long-chain fatty acid defatty-acylase activity is substantially more efficient than its intrinsic deacetylase activity^[3]^[1]. Therefore, HDAC11 influences multiple biological pathways involved in immune regulation, metabolism, and cellular homeostasis^[1]^[4]. In immune signaling, HDAC11 regulates interleukin-10 expression, immune tolerance, and type I interferon signaling, highlighting its role as a key modulator of inflammatory responses^[5]^[6]^[7]. In metabolic systems, HDAC11 participates in adipogenesis, lipid metabolism, energy expenditure, and insulin-related processes, linking the enzyme to obesity and metabolic syndrome models^[4]^[8]. Disease-associated studies further demonstrate involvement of HDAC11 in cancer, neuroinflammation, and immune-mediated disorders, supporting its relevance as a therapeutic target across diverse experimental settings^[1]^[9]. Compared with related HDAC isoforms, HDAC11 exhibits unique substrate specificity and prominent defatty-acylase activity, providing a functional distinction that has stimulated intensive drug-discovery efforts^[1]^[3]. For experimental applications, several selective HDAC11 inhibitors have been developed and are widely used as chemical probes to investigate HDAC11-dependent pathways and evaluate therapeutic potential in disease models^[1]^[10].

References:

[1]. Jia G, et al. Biological function and small molecule inhibitors of histone deacetylase 11. Eur J Med Chem. 2024 Oct 5;276:116634. [Content Brief]

[2]. Ujlaky-Nagy L, et al. Disrupting EGFR-HER2 Transactivation by Pertuzumab in HER2-Positive Cancer: Quantitative Analysis Reveals EGFR Signal Input as Potential Predictor of Therapeutic Outcome. Int J Mol Sci. 2024 May 29;25(11):5978. [Content Brief]

[3]. Núñez-Álvarez Y, et al. HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes. FEBS J. 2022 May;289(10):2771-2792. [Content Brief]

[4]. Chen H, et al. HDAC11, an emerging therapeutic target for metabolic disorders. Front Endocrinol (Lausanne). 2022 Oct 20;13:989305. [Content Brief]

[5]. Villagra A, et al. The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune tolerance. Nat Immunol. 2009 Jan;10(1):92-100. [Content Brief]

[6]. Cao J, et al. HDAC11 regulates type I interferon signaling through defatty-acylation of SHMT2. Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5487-5492. [Content Brief]

[7]. Jung E, et al. Global analysis of AGO2-bound RNAs reveals that miRNAs induce cleavage of target RNAs with limited complementarity. Biochim Biophys Acta Gene Regul Mech. 2017 Nov;1860(11):1148-1158. [Content Brief]

[8]. Skubisz MM, et al. Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000-10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial. EBioMedicine. 2018 Jul;33:276-281. [Content Brief]

[9]. Liu Y, et al. HDAC11: A novel target for improved cancer therapy. Biomed Pharmacother. 2023 Oct;166:115418. [Content Brief]

[10]. Ho TT, et al. Trapoxin A Analogue as a Selective Nanomolar Inhibitor of HDAC11. ACS Chem Biol. 2023 Apr 21;18(4):803-809. [Content Brief]

HDAC11 Inhibitors (69)

HDAC11 Related Products (69):

By Type:	Pan (46) Selective (14)

Cat. No.	Product Name	Effect	Purity

HY-10221

Vorinostat	Inhibitor	99.96%
Vorinostat (SAHA) is a potent and orally active pan-inhibitor of HDAC1, HDAC2 and HDAC3 (Class I), HDAC6 and HDAC7 (Class II) and HDAC11 (Class IV), with ID₅₀ values of 10 nM and 20 nM for HDAC1 and HDAC3, respectively. Vorinostat induces cell apoptosis. Vorinostat is also an effective inhibitor of human papillomaviruse (HPV)-18 DNA amplification.

HY-109015

Tucidinostat	Inhibitor	98.74%
Tucidinostat (Chidamide) is a potent and orally bioavailable HDAC enzymes class I (HDAC1/2/3) and class IIb (HDAC10) inhibitor, with IC₅₀s of 95, 160, 67 and 78 nM, less active on HDAC8 and HDAC11 (IC₅₀s, 733 nM, 432 nM, respectively), and shows no effect on HDAC4/5/6/7/9.

HY-12164

Mocetinostat	Inhibitor	99.68%
Mocetinostat (MGCD0103) is a potent, orally active and isotype-selective HDAC (Class I/IV) inhibitor with IC₅₀s of 0.15, 0.29, 1.66 and 0.59 μM for HDAC1, HDAC2, HDAC3 and HDAC11, respectively. Mocetinostat shows no inhibition on HDAC4, HDAC5, HDAC6, HDAC7, or HDAC8.

HY-15433

Quisinostat	Inhibitor	99.71%
Quisinostat (JNJ-26481585) is a potent and orally active pan-HDAC inhibitor (HDACi), with IC₅₀ values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity. Quisinostat can induce autophagy in neuroblastoma cells.

HY-14842

Givinostat	Inhibitor	98.67%
Givinostat (ITF-2357) is a HDAC inhibitor with an IC₅₀ of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat can be used for Duchenne muscular dystrophy (DMD) research. Givinostat can penetrate the blood-brain barrier (BBB).

HY-182019

HDAC11-IN-5	Inhibitor
HDAC11-IN-5 is a selective, potent and orally active HDAC11 inhibitor with an IC₅₀ of 0.021 μM. HDAC11-IN-5 increases fatty acylation levels of substrate SHMT2 in AML cells. HDAC11-IN-5 induces apoptosis, G1 phase cell cycle arrest, ferroptosis, ROS production and terminal myeloid differentiation in AML cells. HDAC11-IN-5 demonstrates anti-tumor potency in an MLL-AF9-induced mouse AML model. HDAC11-IN-5 can be used for the research of cancer, such as acute myeloid leukemia.

HY-184203

SM-06-09	Inhibitor
SM-06-09 is a potent, highly selective, orally active tetrazolone-based HDAC6 inhibitor with an IC₅₀ value of 0.49 nM. SM-06-09 promotes tumor-associated macrophage (TAM) polarization toward an antitumor M1-like phenotype and enhances macrophage phagocytosis, antigen presentation, and T-cell activation. SM-06-09 remodels the tumor immune microenvironment, exhibits antitumor activity in melanoma models, and enhances the efficacy of anti-PD-1 immune checkpoint blockade.

HY-180811

ALK/HDAC-IN-2	Inhibitor
ALK/HDAC-IN-2 (Compound 19b) is an ALK/HDAC inhibitor with IC₅₀ values for ALK WT and total HDACs of 8 nM and 1.18 μM, respectively. ALK/HDAC-IN-2 exhibits inhibitory activity against ALK mutants G1202R, F1174L, and L1196M, with IC₅₀ values of 2.74, 9.23, and 34.28 nM, respectively. ALK/HDAC-IN-2 shows potent and selective inhibition against HDAC1 (IC₅₀ = 0.24 μM), while its inhibitory activity against HDAC7, HDAC6, and HDAC11 is weak (IC₅₀ > 10 μM). ALK/HDAC-IN-2 has broad-spectrum anti-proliferative activity against various cancer cells, inducing cell cycle arrest and apoptosis. ALK/HDAC-IN-2 can be used for the study of neuroblastoma.

HY-13428

Tubacin	Inhibitor
Tubacin is a potent and selective inhibitor of HDAC6, with an IC₅₀ value of 4 nM and approximately 350-fold selectivity over HDAC1. Tubacin also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2).

HY-13522

Fimepinostat	Inhibitor	99.95%
Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC₅₀ of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively.

HY-18998

LMK-235	Inhibitor	99.61%
LMK-235 is a potent and selective HDAC4/5 inhibitor, inhibits HDAC5, HDAC4, HDAC6, HDAC1, HDAC2, HDAC11 and HDAC8, with IC₅₀s of 4.22 nM, 11.9 nM, 55.7 nM, 320 nM, 881 nM, 852 nM and 1278 nM, respectively, and is used in cancer research.

HY-112285

FT895	Inhibitor	99.84%
FT895 is a potent and selective HDAC11 inhibitor with an IC₅₀ of 3 nM.

HY-13322

Pracinostat	Inhibitor	99.80%
Pracinostat is a potent histone deacetylase (HDAC) inhibitor, with IC₅₀s of 40-140 nM, used for cancer research. Pracinostat also inhibits metallo-β-lactamase domain-containing protein 2 (MBLAC2) hydrolase activity with an EC₅₀ below 10 nM.

HY-128918

SIS17	Inhibitor	99.43%
SIS17 is a mammalian histone deacetylase 11 (HDAC 11) inhibitor with an IC50 value of 0.83 μM. SIS17 inhibits the demyristoylation of serine hydroxymethyltransferase 2, a substrate of HDAC 11, but does not inhibit other HDACs.

HY-16699

Nexturastat A	Inhibitor	98.69%
Nexturastat A is a potent, selective HDAC6 inhibitor. Nexturastat A has inhibitory for HDAC6 with an IC₅₀ of 5 nM. Nexturastat A can be used for the research of multiple myeloma (MM).

HY-14842B

Givinostat hydrochloride monohydrate	Inhibitor	99.63%
Givinostat hydrochloride monohydrate (ITF-2357 hydrochloride monohydrate) is a HDAC inhibitor with an IC₅₀ of 198 and 157 nM for HDAC1 and HDAC3, respectively. Givinostat hydrochloride monohydrate can penetrate the blood-brain barrier (BBB).

HY-145757

Elevenostat	Inhibitor
Elevenostat (JB3-22) is a selective HDAC11 inhibitor with an IC₅₀ of 0.235 µM. Elevenostat can induce apoptosis of multiple myeloma cells and has anti-tumor effect. In addition, Elevenostat inhibits the maturation of mouse oocytes.

HY-15433A

Quisinostat dihydrochloride	Inhibitor	99.05%
Quisinostat dihydrochloride (JNJ-26481585 dihydrochloride) is an orally active, potent pan-HDAC inhibitor with IC₅₀s of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM, and 0.37 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11, respectively. Quisinostat dihydrochloride has a broad spectrum antitumoral activity. Quisinostat dihydrochloride can induce autophagy in neuroblastoma cells.

HY-16012A

Domatinostat	Inhibitor	99.34%
Domatinostat (4SC-202 free base) is a selective class I HDAC inhibitor with IC₅₀ of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. It also displays inhibitory activity against Lysine specific demethylase 1 (LSD1).

HY-126330

SS-208	Inhibitor	99.00%
SS-208 is a selective HDAC6 inhibitor, with an IC₅₀ of 12 nM. SS-208 possesses anti-tumor activity in melanoma.

Name
Email *

	Sorry, but the email address you supplied was invalid.